CN113413386B - 香兰素衍生物在制备治疗结直肠癌合并具核梭杆菌感染药物中的应用 - Google Patents
香兰素衍生物在制备治疗结直肠癌合并具核梭杆菌感染药物中的应用 Download PDFInfo
- Publication number
- CN113413386B CN113413386B CN202110770358.2A CN202110770358A CN113413386B CN 113413386 B CN113413386 B CN 113413386B CN 202110770358 A CN202110770358 A CN 202110770358A CN 113413386 B CN113413386 B CN 113413386B
- Authority
- CN
- China
- Prior art keywords
- fusobacterium nucleatum
- vanillin
- ipm712
- ipm711
- colorectal cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000605986 Fusobacterium nucleatum Species 0.000 title claims abstract description 124
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical class COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 title claims abstract description 98
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 44
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims abstract description 44
- 239000003814 drug Substances 0.000 title claims abstract description 38
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title abstract description 4
- 239000007788 liquid Substances 0.000 claims description 28
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 51
- 230000014509 gene expression Effects 0.000 abstract description 31
- 108090000623 proteins and genes Proteins 0.000 abstract description 31
- 229940079593 drug Drugs 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 20
- 206010028980 Neoplasm Diseases 0.000 abstract description 16
- 206010059866 Drug resistance Diseases 0.000 abstract description 12
- 201000011510 cancer Diseases 0.000 abstract description 12
- 206010027476 Metastases Diseases 0.000 abstract description 10
- 230000009401 metastasis Effects 0.000 abstract description 10
- 210000002421 cell wall Anatomy 0.000 abstract description 7
- 230000009545 invasion Effects 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 5
- 230000003385 bacteriostatic effect Effects 0.000 abstract description 4
- 238000011282 treatment Methods 0.000 description 33
- 239000000243 solution Substances 0.000 description 27
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 25
- 230000001580 bacterial effect Effects 0.000 description 23
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 22
- 235000012141 vanillin Nutrition 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 20
- 239000002609 medium Substances 0.000 description 20
- 238000010186 staining Methods 0.000 description 20
- 239000006228 supernatant Substances 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- 239000001963 growth medium Substances 0.000 description 16
- 239000013642 negative control Substances 0.000 description 14
- 238000002835 absorbance Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 230000000007 visual effect Effects 0.000 description 12
- 210000000170 cell membrane Anatomy 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 229960002949 fluorouracil Drugs 0.000 description 10
- 102000015735 Beta-catenin Human genes 0.000 description 9
- 108060000903 Beta-catenin Proteins 0.000 description 9
- 102000000905 Cadherin Human genes 0.000 description 9
- 108050007957 Cadherin Proteins 0.000 description 9
- 238000009630 liquid culture Methods 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 7
- 229960004316 cisplatin Drugs 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 229960004768 irinotecan Drugs 0.000 description 7
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 7
- 230000035699 permeability Effects 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 101001130509 Homo sapiens Ras GTPase-activating protein 1 Proteins 0.000 description 6
- 108091008611 Protein Kinase B Proteins 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 229940044683 chemotherapy drug Drugs 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 235000013878 L-cysteine Nutrition 0.000 description 4
- 239000004201 L-cysteine Substances 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 102100031426 Ras GTPase-activating protein 1 Human genes 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 239000012984 antibiotic solution Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 229960002433 cysteine Drugs 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 239000010413 mother solution Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000016914 ras Proteins Human genes 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101150053046 MYD88 gene Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 description 3
- -1 PI3KCA Proteins 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 239000013043 chemical agent Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 206010038038 rectal cancer Diseases 0.000 description 3
- 201000001275 rectum cancer Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 2
- 108091006109 GTPases Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 2
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 2
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 2
- 101150005904 RASA1 gene Proteins 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 2
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000003766 bioinformatics method Methods 0.000 description 2
- 229960004117 capecitabine Drugs 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000012757 fluorescence staining Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150072531 10 gene Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000004145 Annexin A1 Human genes 0.000 description 1
- 108090000663 Annexin A1 Proteins 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 230000037060 G2 phase arrest Effects 0.000 description 1
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 1
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 1
- 241000720950 Gluta Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101500023488 Lithobates catesbeianus GnRH-associated peptide 1 Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108010045717 Proto-Oncogene Proteins c-akt Proteins 0.000 description 1
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000005497 Thymidylate Synthase Human genes 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 244000063464 Vitex agnus-castus Species 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000008235 cell cycle pathway Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 235000009347 chasteberry Nutrition 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- MYEGRIHQBUXGCK-UHFFFAOYSA-L disodium;sulfate;dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O MYEGRIHQBUXGCK-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110770358.2A CN113413386B (zh) | 2021-07-07 | 2021-07-07 | 香兰素衍生物在制备治疗结直肠癌合并具核梭杆菌感染药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110770358.2A CN113413386B (zh) | 2021-07-07 | 2021-07-07 | 香兰素衍生物在制备治疗结直肠癌合并具核梭杆菌感染药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113413386A CN113413386A (zh) | 2021-09-21 |
CN113413386B true CN113413386B (zh) | 2022-04-08 |
Family
ID=77720551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110770358.2A Active CN113413386B (zh) | 2021-07-07 | 2021-07-07 | 香兰素衍生物在制备治疗结直肠癌合并具核梭杆菌感染药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113413386B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015038731A1 (en) * | 2013-09-12 | 2015-03-19 | The Johns Hopkins University | Biofilm formation to define risk for colon cancer |
WO2019178215A1 (en) * | 2018-03-13 | 2019-09-19 | Baylor Research Institute | Methods and compositions for treating, prognosing, and diagnosing esophageal cancer |
CN112494467A (zh) * | 2020-12-02 | 2021-03-16 | 浙江大学 | 香兰素在制备尼克酰胺-n-甲基转移酶抑制剂中的应用 |
-
2021
- 2021-07-07 CN CN202110770358.2A patent/CN113413386B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015038731A1 (en) * | 2013-09-12 | 2015-03-19 | The Johns Hopkins University | Biofilm formation to define risk for colon cancer |
WO2019178215A1 (en) * | 2018-03-13 | 2019-09-19 | Baylor Research Institute | Methods and compositions for treating, prognosing, and diagnosing esophageal cancer |
CN112494467A (zh) * | 2020-12-02 | 2021-03-16 | 浙江大学 | 香兰素在制备尼克酰胺-n-甲基转移酶抑制剂中的应用 |
Non-Patent Citations (4)
Title |
---|
A vanillin derivative suppresses the growth or HT29 cells through the Wnt/β-catenin signaling pathway;Wangtong Ma等;《European Journal of Pharmacology》;20190129;第43-48页 * |
IPM712,a vanillin derivative as potential antitumor agents,displays better antitumor activity in colorectal cancers cell lines;Wantong Ma等;《European Journal of Pharmaceutical Sciences》;20200712;第1-8页 * |
各种茶叶的除口臭效果;孙璐西等;《中国茶叶》;19961231(第04期);第28-29页 * |
咖啡酰基类衍生物的合成及其生物活性研究;张娟等;《浙江化工》;20160815(第08期);第14-20页 * |
Also Published As
Publication number | Publication date |
---|---|
CN113413386A (zh) | 2021-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sun et al. | Resveratrol suppresses the growth and metastatic potential of cervical cancer by inhibiting STAT3Tyr705 phosphorylation | |
CN113304151B (zh) | 一种硝基呋喃类小分子化合物在制备诱导铁死亡和/或减缓胃癌化疗耐药药物中的应用 | |
Xia et al. | miR‐31 shuttled by halofuginone‐induced exosomes suppresses MFC‐7 cell proliferation by modulating the HDAC2/cell cycle signaling axis | |
CN108795938A (zh) | 肺腺癌外泌体特异miRNA及其靶基因与应用 | |
CN109295221A (zh) | 环状rna作为结直肠癌分子标志物的应用 | |
CN113413386B (zh) | 香兰素衍生物在制备治疗结直肠癌合并具核梭杆菌感染药物中的应用 | |
CN107190005B (zh) | lncRNA作为生物标志物在肺腺癌诊治中的应用 | |
CN117230132A (zh) | 一种口山酮类化合物Austocystin R的培养方法及制药用途 | |
CN113444765A (zh) | 耐药性乳腺癌治疗药物及其筛选方法 | |
US20210263039A1 (en) | Application of niemann-pick c1 protein in diagnosis and treatment of cancer | |
CN115252599A (zh) | 甘草查尔酮a及光甘草定和甘草查尔酮a的组合物在制备治疗结直肠癌的药物中的应用 | |
CN115317493A (zh) | 一种硼酸类小分子化合物在制备增强免疫检查点抑制剂疗效及治疗白血病药物中的应用 | |
CN111560433B (zh) | 人nufip1的用途及相关产品 | |
CN114164278A (zh) | 一种用于胃癌辅助诊断的标志物及试剂盒 | |
CN111568891B (zh) | 富马酸二甲酯dmf在调节肿瘤代谢、抑制肿瘤生长方面的应用 | |
CN114164270B (zh) | Crip2在检测前列腺癌对多西他赛耐药性及逆转前列腺癌对多西他赛耐药性中的应用 | |
CN111407758A (zh) | 斑蝥素作为miR-214-3p/Wnt/β-Catenin信号通路抑制剂防治骨肉瘤的用途 | |
CN117180238A (zh) | 二十八烷醇在制备预防和/或治疗肺癌药物中的应用 | |
CN110151976B (zh) | Znf496蛋白在提高宫颈癌化疗药物敏感性方面的应用 | |
CN113476456B (zh) | 一种富含连翘脂素的药物组合物及其应用 | |
CN115414355B (zh) | 灵菌红素在制备治疗多发性骨髓瘤的药物中的应用和治疗多发性骨髓瘤的药物 | |
CN114085832B (zh) | 用于抑制PRR14基因的siRNA分子 | |
CN114921520A (zh) | 氯硝柳胺对细胞周期阻滞和凋亡诱导作用的测定方法 | |
Liu et al. | LncRNA FOXD2-AS1 Promotes the Growth, Invasion and Migration of OSCC Cells by Regulating the MiR-185-5p/PLOD1/Akt/mTOR Pathway | |
CN115590861A (zh) | 雷公藤氯内酯醇的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: Room 211, Building 13, Tengfei Science Park, No. 388, Xinping Street, Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone, Jiangsu Province, 215000 Patentee after: Weidu (Suzhou) Biotechnology Co.,Ltd. Address before: 311231 room 312-6, building 1, ChuanHua Kechuang building, ningwei street, Xiaoshan District, Hangzhou City, Zhejiang Province Patentee before: Hangzhou Weidu Biotechnology Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221223 Address after: 311231 room 312-6, building 1, ChuanHua Kechuang building, ningwei street, Xiaoshan District, Hangzhou City, Zhejiang Province Patentee after: Hangzhou Weidu Biotechnology Co.,Ltd. Address before: 730000 No. 222 Tianshui South Road, Chengguan District, Gansu, Lanzhou Patentee before: LANZHOU University |
|
TR01 | Transfer of patent right | ||
CP03 | Change of name, title or address |
Address after: Room 1110-2, 11th Floor, Science and Technology Innovation Building, Room Z101, Building 1, No. 16 Datong Road, High tech Zone, Suzhou City, Jiangsu Province, 215011 Patentee after: Weidu (Suzhou) Biotechnology Co.,Ltd. Country or region after: China Address before: Room 211, Building 13, Tengfei Science Park, No. 388, Xinping Street, Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone, Jiangsu Province, 215000 Patentee before: Weidu (Suzhou) Biotechnology Co.,Ltd. Country or region before: China |
|
CP03 | Change of name, title or address |